IMUX has been the topic of a number of other research reports. Zacks Investment Research downgraded shares of Immunic from a hold rating to a sell rating in a research report on Friday, January 10th. Chardan Capital reiterated a buy rating on shares of Immunic in a research note on Thursday, September 19th.
Shares of NASDAQ IMUX opened at $9.53 on Thursday. Immunic has a 1-year low of $6.20 and a 1-year high of $46.80. The stock’s fifty day moving average is $8.47. The stock has a market cap of $96.42 million, a PE ratio of -0.70 and a beta of 3.51.
Immunic (NASDAQ:IMUX) last posted its earnings results on Thursday, November 7th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.15). On average, equities analysts expect that Immunic will post -3.9 EPS for the current fiscal year.
In other Immunic news, Director Duane Nash sold 4,400 shares of the business’s stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $6.96, for a total transaction of $30,624.00. Following the completion of the sale, the director now directly owns 22,362 shares in the company, valued at approximately $155,639.52. The transaction was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 67.94% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC purchased a new stake in shares of Immunic during the second quarter worth $33,000. Vanguard Group Inc. acquired a new stake in shares of Immunic in the second quarter valued at about $132,000. Finally, BlackRock Inc. purchased a new position in shares of Immunic in the second quarter worth about $145,000. 14.83% of the stock is owned by institutional investors and hedge funds.
Immunic Company Profile
Immunic, Inc, a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies for treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. Its lead development program is IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH, which is in phase II clinical development for treatment of ulcerative colitis and relapsing-remitting multiple sclerosis.
See Also: Analyst Ratings Trading
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.